• Loss for the year up 36.5% to $4.88 million
• Conducted preparations for HERACLES clinical trial of SOF-SKN
• Prioritized development of Sofra and Chroma programs
• Signed further Material Transfer Agreements for Sofra platform

Noxopharm Limited has released its Preliminary Final Report for the year ended 30 June 2025. The company reported a loss of $4,884,170, up 36.5% from the previous year's loss of $3,578,117. During the financial year, Noxopharm conducted extensive preclinical and operational preparations for the HERACLES clinical trial, a first-in-human trial of its drug candidate SOF-SKN for chronic inflammatory diseases. The company also prioritized the development of its Sofra and Chroma programs, particularly the Sofra platform, which offered risk mitigation and increased out-licensing opportunities. Noxopharm signed further Material Transfer Agreements with companies to evaluate the potential of the Sofra platform, and scaled up production and manufacturing of SOF-SKN for the HERACLES trial. The company also announced positive data from its CRO-67 drug candidate targeting pancreatic cancer and released further preclinical data from the Chroma technology platform.

The company did not provide any high-importance, price-sensitive forward-looking financial metrics in the announcement.